Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

Abstract: The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile, Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient.

Abstract: The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient.

Abstract: The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient.

Abstract: One aspect of the invention provides a three-dimensional scaffold including at least one layer of highly-aligned fibers. The at least one layer of highly-aligned fibers is curved in a direction substantially perpendicular to a general direction of the fibers. Another aspect of the invention provides a method for fabricating a three-dimensional scaffold. The method includes: electro spinning a plurality of fibers to produce at least one layer of highly-aligned fibers and forming the at least one layer of highly-aligned fibers into a three-dimensional scaffold without disturbing the alignment of the highly-aligned polymer fibers. A further aspect of the invention provides methods for using a three-dimensional scaffold to treat nerve or spinal cord injury.

Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

Abstract: A ligand component is formed according to formula (1):R12P—X—N?C(R2)—Y, wherein R1 is Ph or Cyc or a C1-C20 substituted or unsubstituted ailkyl group; each Ph is a substituted or unsubstituted phenyl group; each Cyc is a substituted or unsubstituted cycloalkyl group; X is an unsubstituted arylene or a C2-C3 substituted or unsubstituted alkylene; R2 is H, methyl or Ph; and Y N is pyridyl, 6-phenylpyridyl or 6-methylpyridyl; with the proviso that when X is a C2 substituted or unsubstituted alkylene and Y is pyridyl, R2 is methyl or Ph. A reaction product including the ligand component and a metal precursor is prepared by combining the ligand component with the metal precursor. An activated reaction product is formed by activating the reaction product as a hydrosilylation catalyst.

Abstract: A ligand component is formed according to formula (1):R12P—X—N?C(R2)—Y, wherein R1 is Ph or Cyc or a C1-C20 substituted or unsubstituted ailkyl group; each Ph is a substituted or unsubstituted phenyl group; each Cyc is a substituted or unsubstituted cycloalkyl group; X is an unsubstituted arylene or a C2-C3 substituted or unsubstituted alkylene; R2 is H, methyl or Ph; and Y N is pyridyl, 6-phenylpyridyl or 6-methylpyridyl; with the proviso that when X is a C2 substituted or unsubstituted alkylene and Y is pyridyl, R2 is methyl or Ph. A reaction product including the ligand component and a metal precursor is prepared by combining the ligand component with the metal precursor. An activated reaction product is formed by activating the reaction product as a hydrosilylation catalyst.

Abstract: One aspect of the invention provides a three-dimensional scaffold including at least one layer of highly-aligned fibers. The at least one layer of highly-aligned fibers is curved in a direction substantially perpendicular to a general direction of the fibers. Another aspect of the invention provides a method for fabricating a three-dimensional scaffold. The method includes: electro spinning a plurality of fibers to produce at least one layer of highly-aligned fibers and forming the at least one layer of highly-aligned fibers into a three-dimensional scaffold without disturbing the alignment of the highly-aligned polymer fibers. A further aspect of the invention provides methods for using a three-dimensional scaffold to treat nerve or spinal cord injury.

Abstract: Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels.

Abstract: A mattress assembly that includes a lower portion for support of a patient's legs, an upper portion for the support of the patient's torso, and an evacuation assembly. The upper portion including an enclosure defining an interior space and a compressible material within the interior space. The evacuation assembly including a vacuum pump communicating with the interior space and operable to evacuate the interior space and compress the compressible material such that the upper portion of the mattress supporting the patient's torso is lowered with respect to the lower portion of the mattress supporting the patient's legs, and such that the upper portion of the mattress becomes stiffer to facilitate CPR on the patient.